킴스온라인

주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기

최근 해외학술대회의 주요 발표내용을 제공합니다.

컨퍼런스 커버리지

Advances in Inflammatory Bowel Diseases (AIBD) 2024 Annual Conference

09 Dec - 11 Dec, 2024, United States OLD

Does hormone therapy affect IBD outcomes in transgender, nonbinary patients?

2025-02-21

Disease activity, as measured by C-reactive protein (CRP), foecal calprotectin (FC), and endoscopic evaluation, does not significantly vary a year following the initiation of gender-affirming hormone (GAH) therapy in transgender and gender nonconforming patients with inflammatory bowel disease (IBD), as shown in a study presented at AIBD 2024.
IBD linked to increased risk of hidradenitis suppurativa

2025-02-21

Inflammatory bowel disease (IBD) is associated with an increased risk of hidradenitis suppurativa (HS), according to a study presented at AIBD 2024.
Is there a link between mental disorders and IBD?

2025-02-21

Several analyses presented at AIBD 2024 reflect an association between mental disorders and inflammatory bowel disease (IBD).
No increase in CV risk with JAKi vs TNFi for IBD

2025-02-21

Among patients with inflammatory bowel disease (IBD), treatment with Janus kinase inhibitors (JAKi) does not increase the risk of major adverse cardiovascular events (MACE) compared with tumour necrosis factor inhibitors (TNFi), according to a study presented at AIBD 2024.
Novel drug for moderate-to-severe UC yields quality-of-life benefits

2025-02-21

RO7790121, an antibody against tumour necrosis factor-like ligand 1A (Anti-TL1A), helps improve the health-related quality of life (HR-QoL) for patients with moderately to severely active ulcerative colitis (UC), as shown in the phase IIb TUSCANY-2 trial.
OLE data FORTIFY risankizumab role in Crohn’s disease

2025-02-21

Data from the ongoing open-label long-term extension (OLE) of the phase III FORTIFY trial presented at AIBD 2024 support the role of risankizumab for the treatment of moderate-to-severe active Crohn’s disease (CD).
One monoclonal antibody outdoes another in real-world ulcerative colitis study

2025-02-21

The integrin receptor antagonist vedolizumab mostly works as well as the TNF-alpha inhibitor infliximab in biologic-naive patients with moderate-to-severe ulcerative colitis treated in the real-world setting, although vedolizumab slightly surpasses infliximab in terms of inducing endoscopic response and remission while having a better safety profile, according to a study.
Ozanimod delivers real-world clinical benefits in ulcerative colitis

2025-02-21

Treatment with ozanimod (oza) attains high efficacy rates in real-world clinical practice at week 12 for advanced therapy (AT)-naive patients with moderate-to-severe ulcerative colitis (UC) and at week 26 for those with AT exposure, as shown by initial results from POLARIS, an ongoing phase IV open-label study.
SC infliximab biosimilar boosts healing along all bowel segments under colonoscopy in CD

2025-02-21

The efficacy of maintenance with a modified biosimilar of infliximab in promoting healing of inflamed mucosa in CD is observed across all SES-CD segments, a post hoc analysis of the LIBERTY-CD trial has shown

1

최근 본 콘텐츠

최근 본 콘텐츠가 없습니다

TOP

주식회사 킴스

주식회사 킴스 | 광고/제휴문의 | 이용약관 | 개인정보처리방침 | 법적 책임의 한계 | 서비스 전체보기

서울특별시 강남구 테헤란로 8길 33 청원빌딩 1층 (주)킴스
개인정보관리책임자 : 최동섭 사업자등록번호 : 214-81-75415 통신판매업신고 : 강남-5166호 대표이사 : 마사키 타카하타
고객센터 : 1544-2930 (10:00~17:00, 주말/공휴일 제외) 팩스 : 02-3019-9380 e-mail : webmaster@kims.co.kr

Copyright © 1987-2025 KIMS Co., Ltd All Rights Reserved

KIMS 페이스북

KIMS 유튜브